
Tuesday, August 25, 2020 1:09:14 PM
1) control arm outlives treatment arm? (very unlikely for GBM according to what have been known from literature and myriad of presentations from treating doctors);
2) No separation between control and treatment, and/or early and late (crossover) vaccinated patients? (very unlikely according to supposed mechanism of action of DCVax-L, and the suggestion of Dr. Linda Liau in her various presentations);
3) PFS messed up due to pseudo-progression? (may be true initially, but corrected after adjudication. More importantly, as the last patient in the trial lasts five years, PFS really doesn't matter anymore because it is just a surrogate for OS);
4) Treatment effects if any cannot be detected in a statistically significant way, ie, the p value being greater than 0.05? (may be likely due to crossover, but the efficacy can be backed up by comparing to similar external data and some immunogenetics data showing distinct immune-reactions before and after vaccination, etc.);
5) Not a pre-specified group or subgroup shows any statistically significant benefits? (very unlikely); and
6) All of the above or a combination of some of the above? (mostly unlikely)
A quick rough recap on what we have known today before unblinding:
1) mOS for all patients in the trial: about 23.1 months from surgery (compared to the standard of care: 14-17 months); and
2) One year mOS: 89.3 %; two year mOS: 46.4 %s; three year mOS: 28.2 % (based on 2018 updated data); and five year mOS: about 15-17% for all patients according to Les from his recent discussion (compared to standard of care which is about 5% at five years).
Conclusion: DCVax-L will be at least approved for treating GBM based on landmark long-term overall survivals (there are other ways for DCVax-L to get approved as well).
Volume: | - |
Day Range: | |
Bid: | 0.206 |
Ask: | 0.219 |
Last Trade Time: | |
Total Trades: |
Recent NWBO News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
- Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments • AllPennyStocks.com • 01/13/2025 01:56:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/26/2024 10:07:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2024 09:29:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 09:10:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 09:24:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
ConnectM Receives $1.60 Per Share Buyout Offer from its Three Largest Institutional Investors • CNTM • Apr 2, 2025 9:00 AM
Nightfood Holdings Completes Acquisition of Carryout Supplies, Deepening Vertical Integration in AI-Powered Hospitality Automation • NGTF • Apr 2, 2025 8:30 AM
Avant Technologies Partner, Ainnova, to Sponsor and Present at 2025 Healthcare Innovation Summit in Mexico City • AVAI • Apr 2, 2025 8:00 AM
Glidelogic Corp. Unveils ResearchMind - Pioneering AI-Driven Research Innovation for a Global Academic Community • GDLG • Apr 1, 2025 2:10 PM
Fifty 1 Labs, Inc. Celebrates Groundbreaking SpaceX, NASA, and ISS Yeast Experiment by Subsidiary Genetic Networks • FITY • Apr 1, 2025 9:30 AM
North Bay Resources Announces Discovery of Mass Tonnage Gold Deposit up to 149m (489 feet) Grading 0.95 g/t Au, Fran Gold Project, British Columbia • NBRI • Apr 1, 2025 9:00 AM